Pmv Pharmaceuticals Inc (PMVP) - Total Assets
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) holds total assets worth $116.56 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PMVP net asset quality index to measure how much of total assets are equity-financed.
Pmv Pharmaceuticals Inc - Total Assets Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore Pmv Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Pmv Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Pmv Pharmaceuticals Inc's total assets of $116.56 Million consist of 98.9% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pmv Pharmaceuticals Inc (PMVP) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pmv Pharmaceuticals Inc's current assets represent 98.9% of total assets in 2025, an increase from 98.1% in 2018.
- Cash Position: Cash and equivalents constituted 32.6% of total assets in 2025, down from 47.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Pmv Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Pmv Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Pmv Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.09 | 12.22 | 57.79 |
| Quick Ratio | 10.09 | 12.22 | 57.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $103.81 Million | $161.29 Million | $329.16 Million |
Pmv Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Pmv Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -39.1% |
| Total Assets | $116.56 Million |
| Market Capitalization | $58.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pmv Pharmaceuticals Inc's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pmv Pharmaceuticals Inc's assets decreased by 39.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual total assets of Pmv Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $116.56 Million | -39.06% |
| 2024-12-31 | $191.29 Million | -24.14% |
| 2023-12-31 | $252.15 Million | -6.72% |
| 2022-12-31 | $270.31 Million | -18.48% |
| 2021-12-31 | $331.57 Million | -9.29% |
| 2020-12-31 | $365.53 Million | +254.77% |
| 2019-12-31 | $103.03 Million | +62.36% |
| 2018-12-31 | $63.46 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more